Semaglutide

Authoritative sources

• Wikidata (Q27289268)
• MeSH (D000077211)
• Wikipedia

Evidence base

• Randomized Controlled Trial · 2021 · Landmark

  Once-Weekly Semaglutide in Adults with Overweight or Obesity

  New England Journal of Medicine · Wilding JPH, Batterham RL, Calanna S, et al. (STEP 1)

  The pivotal trial that established semaglutide (Wegovy) as a highly effective medication for weight loss in adults without diabetes.

• Phase III Clinical Trial · 2025

  Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

  The New England journal of medicine · Aronne LJ, Horn DB, le Roux CW, Ho W, et al.

• Randomized Controlled Trial · 2025

  Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

  The New England journal of medicine · McGuire DK, Marx N, Mulvagh SL, Deanfield JE, et al.

• Randomized Controlled Trial · 2024

  Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

  The New England journal of medicine · Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, et al.

• Randomized Controlled Trial · 2024

  Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis

  The New England journal of medicine · Bliddal H, Bays H, Czernichow S, Uddén Hemmingsson J, et al.

• Systematic Review · 2024

  Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis

  BMJ (Clinical research ed.) · Yao H, Zhang A, Li D, Wu Y, et al.

• Randomized Controlled Trial · 2023

  Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

  The New England journal of medicine · Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, et al.

• Randomized Controlled Trial · 2022

  Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

  Diabetes, obesity & metabolism · Wilding JPH, Batterham RL, Davies M, Van Gaal LF, et al.

• Randomized Controlled Trial · 2022

  Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

  Nature medicine · Garvey WT, Batterham RL, Bhatta M, Buscemi S, et al.

• Randomized Controlled Trial · 2021

  Once-Weekly Semaglutide in Adults with Overweight or Obesity

  The New England journal of medicine · Wilding JPH, Batterham RL, Calanna S, Davies M, et al.

• Randomized Controlled Trial · 2021

  Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

  JAMA · Rubino D, Abrahamsson N, Davies M, Hesse D, et al.

• Randomized Controlled Trial · 2021

  Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

  The New England journal of medicine · Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, et al.

• Randomized Controlled Trial · 2021

  Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

  Lancet (London, England) · Davies M, Færch L, Jeppesen OK, Pakseresht A, et al.

Where Semaglutide appears on Kindr Health